Cargando…

Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1

Recent data showed that DNA mismatch repair deficiency can be a predictive biomarker for a favorable response of immune checkpoint inhibitors regardless of tumor type due to give rise to high tumor mutational burden (TMB) and microsatellite instability (MSI). Loss-of-function mutations of a specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seo Ree, Chun, Sang Hoon, Kim, Ji Hyun, Kim, Sang-Yeob, Lee, Bo-In, Jung, Chan Kwon, Kang, Jin Hyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Surgical Oncology 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942715/ https://www.ncbi.nlm.nih.gov/pubmed/36945301 http://dx.doi.org/10.14216/kjco.20010

Ejemplares similares

Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
por: Krieger, Tina, et al.
Publicado: (2020)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

Programmed Death Ligand 1-Expressing Classical Dendritic Cells MitigateHelicobacter-Induced Gastritis
por: Go, Du-Min, et al.
Publicado: (2021)

The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy
por: Kim, Seo Ree, et al.
Publicado: (2021)

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
por: Park, Jang-June, et al.
Publicado: (2021)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
por: Li, Wen-Qian, et al.
Publicado: (2020)

Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
por: Liu, Zhuo, et al.
Publicado: (2022)

Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy
por: Kim, Jeong Eun, et al.
Publicado: (2022)

Drain Tube-Induced Jejunal Penetration Masquerading as Bile Leak following Whipple's Operation
por: Bae, Sang Ho, et al.
Publicado: (2011)

The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer
por: Jang, Jae Yeon, et al.
Publicado: (2023)

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
por: Kim, Ryul, et al.
Publicado: (2016)

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

BSBM-14 MOLECULAR PROFILING OF CHECKPOINT LIGANDS AND KEY NK-ACTIVATION AND SUPPRESSIVE LIGANDS BY METASTATIC MELANOMA CELLS
por: Anchan, Akshata, et al.
Publicado: (2023)

Programmed cell death ligand‐1 protein expression and CD274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis
por: Lee, Kyu Sang, et al.
Publicado: (2018)

Status of programmed death-ligand 1 expression in sarcomas
por: Park, Hyung Kyu, et al.
Publicado: (2018)

Do jejunal veins matter during pancreaticoduodenectomy?
por: Kang, Mee Joo, et al.
Publicado: (2022)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer
por: Kim, Seok-Hyun, et al.
Publicado: (2019)

Uncomplicated jejunal diverticulosis with pneumoperitoneum
por: Kwak, Jae Young, et al.
Publicado: (2016)

Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis
por: Kim, Jinchul, et al.
Publicado: (2018)

Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer
por: Shin, Minkyue, et al.
Publicado: (2023)

Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
por: Lee, Kyu Sang, et al.
Publicado: (2021)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
por: Kim, Hye Sook, et al.
Publicado: (2013)

Endoscopic Treatment of Jejunal Heterotopic Gastric Mucosa that Caused Recurrent Intussusception
por: Ahn, Ke Ryun, et al.
Publicado: (2017)

The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer
por: Kwon, Sung Chan, et al.
Publicado: (2023)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition
por: Hakroush, Samy, et al.
Publicado: (2021)

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2017)

Jejunal perforation as an unusual presentation of total colonic aganglionosis in a neonate: A case report
por: Han, Sang Beom, et al.
Publicado: (2017)

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
por: Kim, Ji Hye, et al.
Publicado: (2020)

Hemorrhage from a jejunal polypoid hemangioma: single incisional laparoscopic approach
por: Kye, Bong Hyeon, et al.
Publicado: (2011)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tdiqs4lbp983qkfst8on986n5h